Background: Left ventricular hypertrophy (LVH) is a well-known predictor of cardiovascular mortality in patients who have end-stage renal disease and are maintained on hemodialysis (HD), and LVH is not always correlated with the severity of hypertension in these patients. The purpose of this study was to investigate the role of other factors contributing to LVH.
A lthough hemodialysis (HD) keeps alive patients with end-stage renal disease (ESRD), the survival of these patients is still reduced, 1,2 and despite technologic advances, it has not improved much over the last two decades. 3, 4 Cardiovascular diseases are the most important cause of mortality in HD patients, accounting for about 50% of deaths, 1, 4 rendering the rate of cardiovascular mortality in these patients 20 times greater compared with that in the general population. 5 Indeed, the cardiovascular mortality among ESRD patients in dialysis is still very high even when corrected for the several co-factors involved, 6 regardless of treatment modality. 7 Patients with left ventricular (LV) hypertrophy (LVH), ventricular dilation, or systolic dysfunction have a greater risk of cardiovascular complications and death. Indeed, LVH is the main cardiovascular risk factor and the most powerful predictor of mortality in ESRD patients. 8 Furthermore, LVH regression was found to be associated with improved survival in a prospective cohort of dialysis patients, 9 underlying the importance of this entity as a prognostic marker for the most frequent cause of death in this high-risk population. 2 One of the main factors in the pathogenesis of LVH among ESRD patients is hypertension. Several crosssectional and longitudinal studies have shown the relationship between hypertension and ventricular hypertrophy. 10, 11 However, there are patients with nearnormal blood pressure (BP) and marked LVH, as well as patients with severe hypertension and minimal LVH. In general, the degree of LVH observed in ESRD pa-tients is more pronounced than that encountered in essential hypertension. 12 In HD patients undergoing echocardiography, LVH tended to be more pronounced among patients with more severe hypertension or excessive inter-HD weight gain, 13 suggesting that hypervolemia may be involved in the genesis of the hypertrophy. Reduction of BP was followed by regression of LVH if patients undergoing conventional HD had extended the procedure to the nocturnal period and increased the frequency of HD sessions to six times per week. 14 Another possible cause of LVH can be the increased cardiac output state produced by high-flow arteriovenous fistula, or anemia, as well as the direct effect of hyperparathyroidism. 12 On the other hand, certain antihypertensive medications can exert a beneficial role on the heart independent of hemodynamic effect. 15 In a previous study, we noted that the LV mass index (LVMI) was correlated with BP, cardiac output and cardiac work. However, it was unclear whether the higher cardiac output among patients with greater cardiac hypertrophy was due to anemia, hypervolemia, or the higher flux of the venous access. 16 The primary aim of our current study was to verify the participation of hypervolemia as an LVH factor in addition to the role of hypertension, shifts in blood volume, anemia, hyperparathyroidism, venous access, antihypertensive medication, and adequacy of dialysis on the pathogenesis of LVH in HD. The secondary aim was to evaluate the prognostic impact of LVH in these patients.
Patients and Methods
We performed a cross-sectional study with a follow-up period of up to 2.5 years on a population of 50 HD patients treated at the Dialysis Unit of University Hospital at the Botucatu School of Medicine (São Paulo, Brazil). All patients underwent echocardiography (ECHO) and ambulatory blood pressure monitoring (ABPM) within We performed HD with controlled ultrafiltration machines and polysulfone hollow-fiber dialyzers. Duration of dialysis (3 to 4 hours) and blood and dialyzate flow (500 or 800 mL/min) was prescribed to a Kt/V Ͼ1.3. Ultrafiltration volume and concentration of dialyzate were adjusted individually.
The ECHO procedure was performed according to a previously standardized technique. 17 The following data were recorded: heart rate; systolic and diastolic BP obtained during the examination; systolic and diastolic LV internal dimensions; thickness of the posterior wall and the septum; left atrium and aorta systolic internal dimensions; systolic volume; time of LV ejection; early peak of mitral flow velocity (E); atrial peak filling velocity (A); deceleration time of the E wave; slope of E wave deceleration ramp; and isovolumic relaxation time. These data were used to calculate the relative thickness of the left ventricle, the left atrium/aorta diameter ratio, LV mass, LVMI, fractional shortening percentage of the ventricular diameter, final meridian systolic stress, cardiac output, cardiac index, LV systolic work, and LV systolic work index.
The ABPM was performed with a SpaceLabs 90202 monitor (SpaceLabs, Redmond, WA) during an inter-HD period, that is from the end of an HD session to the beginning of the next (44-h ABPM). Examinations were considered valid if they fulfilled the following criteria 18 : minimum of recording 44 h; and minimum number of valid measurements per hour, three during waking hours and two during sleep. The following parameters were considered for interpretation in the monitoring: BP average of 44 h; and magnitude of nocturnal drop for systolic, diastolic, and pulse pressures.
Blood volume was evaluated by urea kinetics. 19 Clearance of dialysis (K) (mL/min) was calculated from the mass transfer coefficient of the dialyser (KoA), and the blood and dialysate flow. It was multiplied by time of session to estimate dialyzed volume (Kt). The latter was divided by the average of the last three Kt/Vs to yield the estimated blood volume. The prescription parameters were constant for at least 3 months before evaluation. The anthropometric estimate of the volume was calculated by the formula of Hume and Weyers. 20 The difference between volume calculated by urea kinetics and by anthropometrics was defined as excess and was used to classify patients according to the presence of volume excess.
Three groups of patients were arbitrarily separated according to the regression equation between systolic BP over a 44-h period and LVMI Ϫ26.032 ϩ (1.422 ϫ systolic BP) (n ϭ 50; r ϭ 0.512; P Ͻ . 001) (Fig. 1) . The 15 patients who had the maximal deviation of actual LVMI downward from that predicted by the equation were designated as LVMIN; the 15 patients with maximal deviation upwards were designated as LVMAX; and the remaining 20 patients with actual LVMI closest to that predicted by the regression were designated as LVMID.
Results of parametric data are expressed as mean Ϯ SD and non-parametric data as median followed by the interquartile interval for non-parametric data. The 2 test or Fisher's exact test was used when applicable for comparison of frequencies. Linear regression with the Pearson correlation coefficient was used for associations between variables, followed by multiple linear regressions applicable to LVMI and clinical variables (BP, age, time in dialysis, serum albumin, and interdialysis weight gain). Analysis of variance (ANOVA) with the StudentNewmann-Keuls test for multiple comparisons was used for variables with normal distribution; otherwise, the ranksum ANOVA of the Kruskal-Wallis with the Dunn method was used. Survival was calculated by the life-table method and the groups were compared by the method proposed by Greenwood. 21 The association between survival and clinical variables was determined by the Cox proportional hazard regression model. Statistical significance was defined as P Ͻ .05.
Results
Clinical data of the three patient groups are shown in Table 1 . The three groups were comparable for age, weight, height, anthropometically estimated blood volume status, body mass index, body surface area, duration of dialysis sessions, time in HD program, percentage of anuric subjects, and erythropoietin doses. The groups differed regarding inter-HD weight gain, which was significantly larger in the LVMAX. The groups also differed regarding the frequency of patients with volume excess, which was significantly greater in the LVMID group (Table 1) .
There was no statistical difference by ethnicity and gender. African-Brazilians were 13% in LVMIN, 40% in LVMID, and 40% in LVMAX. The percentage of women was 47%, 40%, and 40%, respectively. There were more patients with diabetes in LVMIN (20%) than in the other two groups (5% and 7%, respectively). Smokers were similarly distributed between groups.
The frequency of types of vascular access did not differ between groups. The radial arterio-venous fistula was the most frequent access: 73% in LVMIN, 85% in LVMID, and 87% in LVMAX. Radial graft existed in 13%, 5%, and 7% and total radial accesses was 87%, 90%, and 93%, respectively. The numbers of brachial arterio-venous fistula and brachial and femoral grafts were not significantly different in the three groups.
The groups did not differ in terms of antihypertensive drug class, phosphates binders, calcitriol, or deferoxamine use. Parathyroid hormone, creatinine, hematocrit, albumin, calcium, phosphate, calcium-phosphorus product, Kt/V, sodium, bicarbonate, and residual clearance of urea were comparable among the groups, as shown in Table 2 .
Data from ABPM are shown in Table 3 . The groups also were comparable in terms of systolic and diastolic 44-h ABPM. However, the LVMIN group had a tendency toward a larger nocturnal BP dip than the other two groups, although the difference did not quite achieve statistical significance.
The LV diastolic diameter was significantly greater in LVMAX than in LVMIN, whereas that of LVMID did not differ from the other two groups. The posterior wall and interventricular septum were thicker in LVMAX than in the other two groups. The LV relative wall thickness was larger in LVMAX than in LVMIN, whereas that of LVMID was comparable to the other two groups (Fig. 2) . The left atrium diameter, as well as the left atrium/aorta quotient was lower in the LVMIN than the other two groups. Both LVM and LVMI were significantly different in the three groups: LVMI was greatest in LVMAX (246 Ϯ 35 g/m 2 ), intermediate in LVMID (180 Ϯ 37 g/m 2 ), and smallest in LVMIN (138 Ϯ 33 g/m 2 ) P Ͻ . 05. Fractional shortening, end-systolic meridional stress, and Ca ϫ P ϭ calcium phosphorus product; Kt/V ϭ urea fractional clearance by hemodialysis; other abbreviations as in Table 1 . d ϭ interdialytic diurnal; DBP ϭ diastolic blood pressure; n ϭ interdialytic nocturnal; PP ϭ pulse pressure; SBP ϭ systolic blood pressure; ⌬ ϭ diurnal minus nocturnal BP; other abbreviations as in Table I . * p ϭ .07 v others.
heart rate were similar in the three groups. Cardiac output was higher in LVMAX than in the other two groups and so was the interdialysis weight gain (Fig. 3) . Cardiac index, systolic volume, LV systolic work, and LV systolic work index showed the same trends as cardiac output, but the differences did not reach statistical significance. Diastolic function indices were comparable between groups. Among the variables studied, LVMI was statistically correlated with BP, interdialytic weight gain, and length of participation in the HD program. Linear multiple regression analysis identified only BP and interdialytic weight gain as independent variables associated with LVMI. Survival is illustrated in Fig. 4 . It was significantly lesser in LVMAX the second year after ECHO. Among the studied variables, the Cox proportional hazard regression model selected LVMI and albumin as the variables associated with survival and identified LVMI as the sole independent variable.
The nine deaths during the period of study (five of cardiovascular cause and four of non-cardiovascular cause) were distributed as follows: two deaths in the LVMIN caused by gastric cancer and acute pulmonary edema; two deaths in LVMID caused by complications of central catheter and myocardial infarction; and five deaths in LVMAX caused by acute pulmonary edema, stroke, mesenteric infarct, intestinal occlusion, and myelodysplastic syndrome.
Discussion
Our study identified a number of clinical characteristics, besides BP levels, associated with LVH in ESRD patients, by comparing three groups with the same level of BP and different degrees of LVH. The most important determinants were the nocturnal BP dip and the indices of inter-HD volume expansion. However, the magnitude of nocturnal BP dip was not statistically correlated with the inter-HD volume expansion. The association of LVH with salt and fluid retention was demonstrated by different parameters such as inter-HD weight gain, difference between real and theoretical volumes, cardiac output, LV diameter, and left atrium size. Other known factors that might influence the degree of hypertrophy such as hematocrit, parathyroid hormone, calcium-phosphorus product, markers of nutrition, arterio-venous proximal fistulas, and medications were similar among the groups.
The association of greater LV diameter, cardiac output, and size of left atrium with larger cardiac mass is considered to be indirect evidence of the participation of hypervolemia in the pathogenesis of LVH, because in HD patients these parameters correlate with the direct measure of blood volume. 22 The two groups with LVMI that was equal to or less than that predicted by systolic BP according to the regression equation (designated as LVMIN and LVMID, respectively), had the same inter-HD weight gain, even though the LVMID group had a greater LVMI and included more patients with hypervolemia. Thus, despite similar inter-HD weight gain, these groups were left with different volume status after HD. To evaluate the status of volume expansion in HD patients, it is necessary either to quantify the inter-HD fluid accumulation or to indirectly assess post-dialysis volume overload. 23 The presence of a larger left atrium diameter in the LVMID, as well as the tendency to a larger ventricular diameter, corroborate this premise.
Not all studies have confirmed a relationship between inter-HD weight gain and cardiac hypertrophy. However, some were carried out with electrocardiography, not ECHO 24 ; others observed minimal inter-HD weight gain 25 ; and still others had patients with severe anemia, which may have been the overriding factor in their patients. 26 Consistent with our data, Wu et al 27 reported an association of inter-HD weight gain with LVH but not with BP, whereas others did find an association of this parameter with BP. 28 Foley et al, 29 studying patients based on United States Renal Data System records, observed increased mortality in patients with larger inter-HD weight gain and an independent impact of BP measured before and after HD. Our finding that the LVMAX with a greater inter-HD weight gain, despite similar BP had a poorer survival than the other two groups is consistent with the notion that LVH is a marker of poor prognosis. These findings underline the importance of correct management of inter-HD weight gain to prevent higher volume variation in the inter-HD period. Bleyer et al 30 and Karnik et al 31 noted that death rates in HD are highest during the longer inter-HD period (ie, a 3-day interval between HD sessions), coinciding with larger volume accumulation.
It should be noted, however, that some studies have reported association of HD weight gain with better nutritional status 32 and too limited inter-HD weight gain with depression and acute psychological stress, 33 leading to inadequate nutrition and poorer prognosis. 34 Since sodium ingestion accompanies consumption of all nutrients, ideally an enhanced ingestion of proteins and calories should be dissociated from sodium intake. Indeed, ingestion of 8 g of salt in an anuric patient will force, by osmotic mechanism, the ingestion of 1 L of free water or weight gain of 1 kg. Thus, a weight gain of 4 kg indicates ingestion of 32 g of salt in the inter-HD period, 35 and this excessive sodium overload is a cardiovascular risk factor. Our LVMAX patients had inter-HD weight gain of 750 g more than the other groups, suggesting an excess of ϳ6 g of sodium.
In conclusion, we found that three groups of patients with LVMI greater than, equal to, or less than that predicted for their level of BP, differed mostly in terms of markers of hypervolemia. The group with more cardiac hypertrophy had the greatest inter-HD weight gain and least survival when compared with the other two groups. Average BP was similar in the three groups, although there was a difference in night dipping pattern, which was more pronounced in the LVMIN group. The data suggest an independent association between inter-HD weight gain, LVH, and prognosis in HD patients, indicating that cardiac hypertrophy and cardiovascular mortality are not necessarily correlated with conventionally measured BP levels.
